Loading...

INOVIQ Ltd

IIQ.AX•ASX
HealthcareMedical - Diagnostics & Research
A$0.45
A$0.01(3.45%)

INOVIQ Ltd (IIQ.AX) Company Profile & Overview

Explore INOVIQ Ltd’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

INOVIQ Ltd (IIQ.AX) Company Profile & Overview

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.

SectorHealthcare
IndustryMedical - Diagnostics & Research
CEODr. Leearne Maree Hinch B.Sc., B.V.M.S., BSc., M.B.A., M.R.C.V.S.

Contact Information

https://www.inoviq.com
61 3 9548 7586
23 Normanby Road, Notting Hill, VIC, 3168

Company Facts

15 Employees
IPO DateJan 28, 1988
CountryAU
Actively Trading

Frequently Asked Questions